Quantcast

Latest Prostate cancer Stories

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-07 16:28:19

Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones -- Apatorsen -- The OncoGenex apatorsen development program includes seven Phase 2 trials in four tumor types,...

2014-08-06 16:28:56

--Brand Expands New Apparel and Accessories to Successful Pediatric, Breast, and Prostate Cancer Awareness Collections, Aiding in the Fight Against Cancer-- IRVINE, Calif., Aug. 6, 2014 /PRNewswire/ -- ASICS America is proud to announce its third year of cancer awareness product collections with the ASICS Accelerate Hope(TM) initiative. Based on the results of two consecutive years of successful cancer cause campaigns, ASICS has amplified the Accelerate Hope(TM) program to include...

2014-08-06 12:29:18

The Majority of Surveyed Non-Prescribers Anticipate Prescribing Xofigo Within the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that at one year post-launch in the United States, over two thirds of surveyed U.S. medical oncologists have prescribed Bayer HealthCare's alpha-emitting radiopharmaceutical Xofigo. The majority of current non-prescribers indicated that they expect to prescribe...

2014-08-06 12:28:13

Study Correlates Immune Response with Improved Survival in Prostate Cancer Patients after Receiving the Antigen Express Novel Immunotherapeutic AE37 WORCESTER, Mass. and TORONTO, Aug. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune...

2014-08-06 08:31:58

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(®) Genomic Prostate Score (GPS) predicts...

2014-08-05 12:31:41

Active Surveillance Provides Low-Risk Patients Less Harmful Treatment Option NORTHFIELD, Ill., Aug. 5, 2014 /PRNewswire-USNewswire/ -- Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. Pathologists help determine patient eligibility for active surveillance and today a multi-specialty team published their recommendations for...

2014-08-05 12:31:30

9th Annual Race Supports Lung Cancer Research SOUTHAMPTON, N.Y., Aug. 5, 2014 /PRNewswire-USNewswire/ -- Strides for Life 9 will return to Southampton, NY at 8:45 a.m. on Sunday, August 10, 2014. The 3-mile fun run/walk around scenic Lake Agawam was the first ever of its kind to support lung cancer research and is a signature event of the Lung Cancer Research Foundation (LCRF, www.lungfund.org). LCRF funds critical lung cancer research grants at leading cancer research institutions...

2014-08-05 08:33:58

POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB: GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells. He also shares insight into the key points that make them different from competitive...

2014-08-05 08:28:20

Demands Manufacturers Prove Claims of Safety and Benefits For Prostate Cancer Treatments CORAL SPRINGS, Fla., Aug. 5, 2014 /PRNewswire/ -- A prominent Florida prostate cancer specialist is leading a groundswell of physicians and prostate cancer patients challenging the efficacy of a popular robotic surgical treatment marketed and promoted into near ubiquitous use in hospitals across the nation. In an extensive article...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related